__NUXT_JSONP__("/drugs/Indatuximab_Ravtansine", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"An immunoconjugate consisting of a monoclonal antibody directed against syndecan-1 (CD138) covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Upon administration, indatuximab ravtansine binds to syndecan-1-expressing tumor cells; upon internalization the DM4 moiety is released, binding to tubulin and disrupting microtubule assembly\u002Fdisassembly dynamics, which may result in the inhibition of cell division and cell growth of syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.",fdaUniiCode:"XGL4M23834",identifier:"C78840",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129823","C1512"],synonyms:["Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062","BT-062","BT062","INDATUXIMAB RAVTANSINE",c,"Maytansinoid-Conjugated Anti-Myeloma Monoclonal Antibody BT062"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FIndatuximab_Ravtansine",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Indatuximab_Ravtansine","Indatuximab Ravtansine","2021-10-30T13:45:18.643Z")));